Knopp plans to phase development development of KNS-760704 in ALS in late 2009.

Phase 2 studies of KNS-760704 in ALS are ongoing. The compound was obtained Orphan Drug Designation by the U.S. Food and Drug Administration and the European Commission for the treatment of patients with ALS.. Knopp plans to phase development development of KNS-760704 in ALS in late 2009.About KNS-760704. KNS – 760704 is a low molecular weight benzothiazole improve proven mitochondrial function and to confer significant cellular protection in neurons under stress , the chirally pure form of synthetic benzothiazole -2-amino-4,7 – tetrahydro-6 – benzothiazole is KNS-760704 a high oral bioavailability, soluble in water, is excreted renally and only moderately protein bound. Weakness and wasting. ALS. The compound was safe and well tolerated in healthy subjects.

Who is more susceptible to hypothermia? Elderly people with inadequate food, clothing or heating 2 Babies sleeping in cold bedrooms 3 People who remain outdoors over an extended period anytime fourth People who drink alcohol or use illegal drugs. Where am I going about about hypothermia? There are several ways to find more information about hypothermia – .This data provides a substantial degree of growing within GSK oncology portfolio – demonstrating the company’s commitment in the oncology area and strength of his late-stage pipelined. Newest built GSK Oncology ‘.

– 13.30 EST results from the Phase II study of pazopanib in women with advanced epithelial ovarian, fallopian tubes and the peritoneal cancer diseases to be be presented at the ESMO press, Saturday, September, 30 – for on the latest GSK Oncology media materials.

Both comments and pings are currently closed.

Comments are closed.

Powered by WordPress | Designed by: | Thanks to